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Rationale: Idiopathic pulmonary fibrosis (IPF) is a chronic dysregulated
response to alveolar epithelial injury with differentiation of epithelial
cells and fibroblasts into matrix-secreting myofibroblasts resulting in
lung scaring. Theprognosis is poor and therearenoeffective therapies
or reliable biomarkers. Galectin-3 is ab-galactoside binding lectin that
is highly expressed in fibrotic tissue of diverse etiologies.
Objectives: To examine the role of galectin-3 in pulmonary fibrosis.
Methods: We used genetic deletion and pharmacologic inhibition in
well-characterizedmurinemodels of lungfibrosis. Furthermechanistic
studieswere performed in vitro andon samples frompatientswith IPF.
Measurements andMain Results: Transforming growth factor (TGF)-b
and bleomycin-induced lung fibrosis was dramatically reduced in
mice deficient in galectin-3, manifest by reduced TGF-b1–induced
EMT and myofibroblast activation and collagen production.
Galectin-3 reduced phosphorylation and nuclear translocation of
b-catenin but had no effect on Smad2/3 phosphorylation. A novel
inhibitor of galectin-3, TD139, blocked TGF-b–inducedb-catenin ac-
tivation in vitro and in vivo andattenuated the late-stageprogression
of lung fibrosis after bleomycin. There was increased expression of
galectin-3 in the bronchoalveolar lavage fluid and serum from
patientswith stable IPF comparedwith nonspecific interstitial pneu-
monitis and controls, which rose sharply during an acute exacerba-
tion suggesting that galectin-3 may be a marker of active fibrosis in
IPF and that strategies thatblockgalectin-3maybeeffective in treat-
ing acute fibrotic exacerbations of IPF.
Conclusions: This study identifies galectin-3 as an important regula-
tor of lung fibrosis and provides a proof of principle for galectin-3
inhibition as a potential novel therapeutic strategy for IPF.
Keywords: fibrosis; epithelial cells; fibroblasts
Idiopathic pulmonary fibrosis (IPF) is a chronic condition of
unknown etiology with repeated acute lung injury causing pro-
gressive fibrosis resulting in deteriorating lung function. The
median time to death from diagnosis is 2.5 years (1) and the
incidence of IPF continues to rise (2, 3). No specific therapy is
available and there are no reliable biomarkers to predict dis-
ease progression.
IPF is characterized by fibroblastic foci containing fibroblasts and
myofibroblasts, which show increased activation response to fibro-
genic cytokines, such as transforming growth factor (TGF)-b1 (4–6).
Given the nonresponsiveness of many cases of IPF to current anti-
inflammatory treatments (7–9) the myofibroblasts within fibroblas-
tic foci represent a potential novel therapeutic target.
Myofibroblasts may arise from resident parenchymal fibro-
blasts, from circulating precursor cells, or from lung epithelial cells
by a process of epithelial to mesenchymal transition (EMT) (10).
EMT is characterized by loss of epithelial markers, such as
E-cadherin; cytoskeletal reorganization; and transition to a spindle-
shaped morphology with the acquisition of mesenchymal markers
(a-smooth muscle actin [a-SMA] and collagen I) (11, 12). EMT of
alveolar epithelial cells (AECs) has been widely observed in
patients with IPF (4). TGF-b is a major inducer of EMT and
a key mediator of fibrosis in many tissues including lung (13).
Adenoviral vector delivery of active TGF-b1 directly into rodent
lung results in severe and progressive fibrosis with features of
human disease including fibroblastic foci and honeycombing
(14–16) and is an ideal model to evaluate the mechanisms regu-
lating lung fibrosis.
Galectin-3 is a b-galactoside binding lectin that is highly
expressed in fibrotic tissue of diverse etiologies. Previous work
has shown that galectin-3 plays a key role in liver and kidney
fibrosis (17, 18). This study examined the role of galectin-3
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AT A GLANCE COMMENTARY
Scientific Knowledge on the Subject
Idiopathic pulmonary fibrosis has a poor prognosis and there
are no effective therapies or reliable biomarkers. Trans-
forming growth factor (TGF)-b is a key mediator of fibrosis.
Galectin-3 is highly expressed in fibrotic tissue of diverse
etiologies and knocking out galectin-3 reduces liver and
kidney fibrosis after profibrotic insults. The role of galectin-3
in pulmonary fibrosis and the mechanisms by which galectin-
3 affects TGF-b function and fibrosis is unknown.
What This Study Adds to the Field
This study demonstrates that galectin-3 regulates TGF-b
function and the pathogenesis of lung fibrosis and high-
lights the potential importance of galectin-3 inhibitors as
a potential new therapy for this disease.
in bleomycin and TGF-b1–induced lung fibrosis in mice and estab-
lishes its relevance in human IPF. We show that galectin-3 inhibi-
tion may represent a novel therapeutic strategy for treatment of
lung fibrosis. Some of the results of these studies have been pre-
viously reported in the form of abstracts (19, 20).
METHODS
Animals
C57/Bl6 mice were maintained in 12-hour light, 12-hour dark cycles with
free access to food and water. All procedures were performed in accor-
dance with Home Office guidelines (Animals [Scientific Procedures]
Act 1986). Generation of strain matched galectin-32/2 mice by gene-
targeting technology as previously described (21).
TGF-b1 Adenovirus-induced Lung Fibrosis
TGF-b1 adenovirus (Ad-TGF-b1223/225) or control virus (Ad-DL) was
prepared and treated as previously described (14, 15). This virus
expresses active TGF-b1 in the lung over a period of 7–14 days and
produces extensive and progressive fibrosis in rats and mice (14–16, 22).
Mice received 2 3 108 plaque-forming units (PFU) virus in 50-ml sterile
saline intratracheally and were culled 5 or 14 days after instillation.
Bleomycin-induced Lung Fibrosis
Female mice received saline or bleomycin intratracheally (33 mg in 50 ml
of saline). Mice were culled on Days 15, 21, or 32 by terminal anesthesia.
Determination of Lung Fibrosis and Inflammation
Collagen content in the left lung was determined by sircol assay as per
manufacturer’s instructions. Histologic lung inflammation and fibrosis
score was performed in Masson trichrome–stained sections (23).
Immunohistochemistry
Paraffin-embedded sections of mouse tissue were stained with Masson’s
trichrome and hematoxylin and eosin as per manufacturer’s instruc-
tions. Sections were processed for immunohistochemistry as described
previously (18) and the following primary antibodies used: mouse
monoclonal anti–a-SMA clone 1A4 (Sigma, Poole, UK); rat monoclo-
nal antimouse galectin-3 clone 8942F (Cedarlane, ON, Canada); and
mouse antiactive (ABC) b-catenin (Millipore, Watford, UK). Sections
were quantified as previously described (18).
Isolation of Murine Primary Lung Fibroblasts and Primary
Type II AECs
Primary cultures of lung fibroblasts were isolated by collagenase digestion
(0.5 mg/ml for 1 h at 378C) of minced lungs and digests passed through
a 100-mm cell strainer. Cells were cultured in Dulbecco’s modified Eagle
medium containing 10% fetal calf serum for 4 days until confluent. Lung
fibroblasts were used at passage 2. Lung AECs were extracted following
the method originally described by Corti and coworkers (24), which gave
rise to AEC yields of greater than 95% purity.
Immunofluorescence
Immunofluorescence was performed using the following primary anti-
bodies: mouse monoclonal anti–a-SMA antibody clone 1A4 (Sigma);
rabbit polyclonal anti–b-catenin antibody (Sigma); rabbit anti-mouse
collagen-1; mouse anti–active b-catenin (ABC; Millipore); and rabbit
anti-mouse CD34 (Santa Cruz Biotechnology, Santa Cruz, CA). Cells
were fixed in 3% paraformaldehyde and stained with the previously
mentioned antibodies followed by species-specific Alexa-488– or
Alexa-568–conjugated secondary antibodies (Invitrogen, Paisley, UK)
and fluorescence microscopy.
Statistical Analysis
Results are presented as means 6 SEM. Significance of the differences
between means was assessed using one-way analysis of variance or two-
tailed Student t test. Values of P less than 0.05 were considered signif-
icant. Unless stated otherwise, studies were performed on three to six
independent occasions.
Expanded methods including reagents, assay for replication-competent
adenovirus, RNA extraction, quantitative polymerase chain reaction,
Western blotting, TGF receptor binding, and flow cytometric analysis
of lung digests are provided in the online supplement.
RESULTS
Galectin-32/2 Mice Show Reduced Lung Fibrosis in Response
to TGF-b1 Adenovirus
Intratracheal administration of adenoviral TGF-b1 (Ad–TGF-b1)
in wild type (WT) mice stimulates the formation of fibroblast
foci with marked fibrotic changes at Day 14, evidenced by in-
creased collagen staining in interstitial areas of the lung. By con-
trast fibrosis was markedly reduced in galectin-32/2 mice (Figure
1A), as quantified for collagen content by sircol assay and fibrosis
Figure 1. Galectin-32/2 mice show reduced
lung fibrosis after intratracheal adenoviral
transforming growth factor (TGF)-b1 com-
pared with wild-type (WT) mice. WT C57/
Bl6 mice or galectin-32/2 mice (G-32/2) re-
ceived 2 3 108 plaque-forming units (PFU)
adenoviral TGF-b1 (Ad-TGF-b) or control vi-
rus (control) and lungs were harvested after
14 days. (A) Lung sections were stained with
Masson trichrome (scale bar ¼ 100 mm). Pic-
tures are representative of n ¼ 6 per group.
(B) Serial lung sections were immunostained
for galectin-3 and showed spatial localiza-
tion within fibrotic areas of lung (scale
bar ¼ 20 mm). (C) Total lung collagen was
quantified by sircol assay. (D) Fibrosis was
quantified by histologic score from Masson-
stained sections. (E) Galectin-3 was in-
creased in the bronchoalveolar lavage fluid
from WT mice after Ad-TGF-b. (F) TGF-b1
levels were increased in the bronchoalveolar
lavage fluid from WT and galectin-32/2mice
after Ad-TGF-b. n ¼ 6 per group. * P , 0.01
compared with WT.
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scoring (Figures 1C and 1D). In WT mice, galectin-3 expression
was observed in alveolar macrophages and in the bronchial epi-
thelium (Figure 1B) and was temporally and spatially related to
fibrosis. Ad–TGF-b1 produced the same marked increased ex-
pression of active TGF-b1 in the bronchoalveolar lavage (BAL)
fluid from Days 2–6 after instillation (Figure 1F) and the same
modest degree of inflammation, inflammatory cell recruitment,
and combined inflammatory score in WT and galectin-32/2 mice
(see Figure E1 in the online supplement). Thus galectin-32/2
mice showed significant attenuation of TGF-b1–induced fibrosis
despite similar initial tissue responses and inflammatory cell
recruitment.
Galectin-32/2 Fibroblasts Show Reduced Activation
and Collagen Production in Response to TGF-b1
Equal yields of fibroblasts were obtained from WT and galectin-
32/2 mice. TGF-b1 induced a marked change in morphology
and increase in collagen synthesis in primary lung fibroblasts iso-
lated fromWTmice that was abrogated in galectin-32/2 lung fibro-
blasts (Figure 2A). Myofibroblast activation in response to TGF-b1
was significantly reduced with markedly lower collagen-1 and
a-SMA expression in galectin-32/2 compared with WT lung
fibroblasts as judged by Western blot analysis (Figure 2B) and
sircol assay (Figure 2C). There was no difference in prolifera-
tion between WT and galectin-32/2 primary lung fibroblasts
(see Figure E2).
Galectin-32/2 AECs Show Reduced EMT in Response
to TGF-b1
EMT is a major source of pathogenic myofibroblasts during pul-
monary fibrogenesis (25). EMT-myofibroblast activation in re-
sponse to TGF-b1 was determined in AECs isolated from WT
and galectin-32/2 mice. Equal yields of AECs were obtained
fromWT and galectin-32/2mice. At Day 2 after isolation AECs
formed islands of cobblestone-shaped clusters with E-cadherin
staining at the cell junctions (Figure 3A). TGF-b1 treatment for
72 hours altered WT AEC morphology from a confluent cobble-
stone appearance with surface E-cadherin staining to spindle-shaped
with loss of cell–cell contacts and increased a-SMA immunofluo-
rescence staining. Treatment with TGF-b1 also increased galectin-
3 secretion in WT AECs as measured by ELISA (Figure E2). By
contrast, galectin-32/2AECs maintained E-cadherin surface stain-
ing and reduced up-regulation of a-SMA (Figures 3A and 3B).
This was confirmed by Western blot analysis, which showed that
TGF-b1 induced a marked up-regulation of mesenchymal markers
a-SMA and vimentin and down-regulation of the epithelial marker
E-cadherin in WT AECs, which was evident after 48 hours. By
contrast, TGF-b1 did not stimulate a-SMA expression or down-
regulate E-cadherin in galectin-32/2 AECs (Figure 3B). Western
blot analysis and reverse transcriptase polymerase chain reaction
demonstrate that TGF-b1–induced a-SMA up-regulation is re-
duced in galectin-32/2 AECs (Figure 3C) and restored by the
addition of 25 mg/ml of recombinant galectin-3 (Figure 3C). Fur-
thermore, galectin-3 deletion reduced TGF-b1–induced migration
in a scratch wound assay (Figure 3D). Thus, TGF-b1–induced
EMT in AECs is dependent on galectin-3.
Regulation of TGF-b1 Receptor Function and Signaling
by Galectin-3
We examined themechanisms by which galectin-3 regulates TGF-
b1–induced EMT and myofibroblast activation. Western blot
analysis shows that TGF-b receptor II (TGFR-II) is equally
expressed in WT and galectin-32/2 cells (Figure 4A, left) and
that knock down of galectin-3 in human alveolar epithelial
A549 cells does not affect total TGFR-II expression (Figure
4A, right). We therefore examined the effect of galectin-3 on
TGFR-II function and downstream signaling in lung epithelial
cells. Human lung epithelial cells were transfected with siRNA
to human galectin-3 and treated with lactose to remove surface
galectin-3. This produced greater than 90% reduction in galectin-3
expression in A549 cells. Removal of galectin-3 reduced the num-
ber of surface TGF-b receptors measured by radioligand binding
(control Kd ¼ 106 6 21 pM; Bmax ¼ 5.54 6 1.11 fmoles/mg
protein, siRNA Kd ¼ 67 6 19 pM; Bmax ¼ 1.25 6 0.56 fmoles/
mg protein) (Figure 4B). Addition of 25 mg/ml recombinant hu-
man galectin-3 during the last 18 hours of the transfection re-
stored TGFbR-II binding to control levels (Kd ¼ 88 6 15 pM,
Bmax ¼ 3.866 1.02 fmoles/mg protein) (Figure 4B). These results
show that galectin-3 regulates the expression of TGF-b receptors
at the cell surface. This was further assessed by flow cytometry.
Figure 4C shows that in control A549 cells 88% of cells expressed
TGFR-II compared with only 22% in A549 cells treated with
siRNA to galectin-3. This was reduced to 15% in control cells
and 9% in galectin-3 depleted cells after 2-hour treatment with
TGF-b.
Figure 2. Galectin-32/2 primary lung fibroblasts show reduced collagen
production in response to transforming growth factor (TGF)-b1 com-
pared with wild-type (WT) fibroblasts. Primary lung fibroblasts from
WT and galectin-32/2 lungs were incubated with or without 5 ng/ml
TGF-b1 for 48 hours. (A) Immunofluorescence staining for a-smooth
muscle actin (a-SMA) (green) and collagen-1 (red) showing reduced
a-SMA and collagen-1 expression in galectin-32/2 fibroblasts after
TGF-b1 (scale bar ¼ 15 mm). Nuclei are stained with 49,6-diamidino-2-
phenylindole (DAPI, blue). (B) Reduced a-SMA and collagen-1 expression
in TGF-b1–treated galectin-32/2 fibroblasts compared with WT fibro-
blasts as measured by Western blot analysis. (C) Galectin-32/2 lung
fibroblasts produced less collagen compared with WT fibroblasts as de-
termined by sircol assay (n ¼ 4; * P , 0.05 compared with WT).
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SiRNA-mediated knockdown of galectin-3 had no effect on
TGF-b1–induced Smad3 or Smad2 phosphorylation as demon-
strated by Western blot analysis using a phosphospecific antibody
to Smad3 and Smad2/3 (Figure 4D). However, down-regulation of
galectin-3 blocked TGF-b1–induced b-catenin activation in A549
cells (Figure 4D) using an antibody that recognizes an active form
of b-catenin (dephosphorylated on Ser37 and Thr41) but had no
effect on b-catenin phosphorylation at tryosine 654. To examine
Figure 3. Primary lung alveolar epithelial
cells (AEC) from galectin-32/2mice show
reduced epithelial to mesenchymal tran-
sition (EMT) in response to transforming
growth factor (TGF)-b1 in vitro com-
pared with wild-type (WT) AECs. (A)
WT and galectin-32/2 (G-32/2) AECs
3 days after isolation were untreated
(Day 0; i and iv) or cultured for 48 hours
in the presence (iii and vi) or absence (ii
and v) of 5 ng/ml TGF-b1. Cells were
examined by immunofluorescence for
E-cadherin (red) and a-smooth muscle
actin (a-SMA) (green) expression (scale
bar ¼ 100 mm). (B) Primary AECs treated
with TGF-b1 were lysed and analyzed for
galectin-3, a-SMA, vimentin, E-cadherin,
and b-actin expression by Western blot
analysis. (C) Galectin-32/2 AECs were
cultured for 48 hours with 5 ng/ml
TGF-b1 in the presence or absence of
25 mg/ml recombinant galectin-3 and
compared with WT AECs treated with
TGF-b1. a-SMA, E-cadherin, and b-actin
protein expression was analyzed by
Western blot analysis and a-SMA tran-
script expression was analyzed by re-
verse transcriptase polymerase chain
reaction. (n ¼ 4). (D) Confluent cultures of WT and galectin-32/2 lung epithelial cells were wounded and treated with or without 5 ng/ml
TGF-b1. Migration into the scored region was observed by phase contrast microscopy.
Figure 4. The effect of galectin-3 on
transforming growth factor (TGF)-b re-
ceptor binding, Smad, and b-catenin sig-
naling in A549 alveolar epithelial cells
(AEC). (A) Western blot analysis of total
TGFR-II in whole cell lysates from wild-
type and galectin-32/2 primary AEC and
human A549 cells treated with and with-
out galectin-3 siRNA. (B) Galectin-3 ex-
pression was inhibited by siRNA in
human A549 cells and cells were treated
with 125I-TGF-b1 for 3 hours at 48C,
washed, and binding determined by scintil-
lation counting (solid squares). Inhibition of
galectin-3 expression reduced 125I–TGF-b
receptor binding by a reduction in Bmax
with no significant effect on TGF-b1 bind-
ing affinity (open circles). Receptor binding
was restored when cells were pretreated
for 18 hours with 25 mg/ml recombinant
galectin-3 (open squares). (C) TGFR-II ex-
pression measured by flow cytometry in
control and galectin-3–depleted cells trea-
ted with or without 10 ng/ml TGF-b1 for 2
hours. (D) Inhibition of galectin-3 expres-
sion has no effect on Smad2/3 phosphory-
lation but reduces b-catenin activation.
A549 were transfected with siRNA duplexes targeting galectin-3 and treated with TGF-b1 at concentrations as indicated for 30 minutes. Lysates were
immunoblotted for pSmad3, pSmad2/3, total Smad3, Y654-b-catenin, active-b-catenin, total b-catenin, and b-actin. Galectin-3 blots show efficient
knockdown of expression in siRNA-treated cells. There was no difference in Smad2 or 3 phosphorylation after galectin-3 inhibition.
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this effect in primary cells, AECs were isolated from WT and
galectin-32/2 mice. TGF-b1 induces b-catenin translocation to
the nucleus inWTAECs, whereas in galectin-32/2AECs b-catenin
expression is maintained at the cell surface after TGF-b1 stimu-
lation (Figure 5A). b-catenin transcriptional activity as measured
by activation of the Tcf/Lef reporter construct was reduced in
TGF-b1–treated galectin-32/2 AECs (Figure 5C). Furthermore,
there was no difference in TGF-b1–induced Smad3 phosphory-
lation or Smad3 expression in WT or galectin-32/2 primary
AECs (Figure 5B); however, basal and TGF-b1–induced increase
in active b-catenin seen in WT AECs was reduced in galectin-
32/2 AECs (Figure 5B). Furthermore, addition of recombinant
galectin-3 to primary epithelial cells had no effect on b-catenin
activation on its own (see Figure E3) but potentiated the effect
of TGF-b. The Wnt signaling pathway mediates b-catenin acti-
vation by regulating the phosphorylation and activity of GSK-
3b; GSK-3b activity is inhibited by the PI3K/AKT pathway by
AKT-mediated phosphorylation of GSK-3b at ser9. Using an
antibody that recognizes ser9 phosphorylated GSK-3b we show
reduced phosphorylation (both basally and in response to TGF-
b1) in galectin-32/2 epithelial cells compared with WT cells
(Figure 5B) with a concomitant reduction in AKT phosphory-
lation. Together our data support the hypothesis that galectin-3
does not affect TGF-b–mediated Smad activation but does aug-
ment b-catenin activation by inhibiting GSK-3b activity. In vivo
Ad–TGF-b1 also induced marked b-catenin activation and nu-
clear translocation. In galectin-32/2 mice Ad–TGF-b1 did not
significantly increase b-catenin activation compared with con-
trol despite good expression of active TGF-b1 (Figures 5D and
1F). Thus, galectin-3 regulates TGF-b1–mediated b-catenin
and EMT-myofibroblast activation in a Smad-independent
manner.
Galectin-3 Is Elevated in Human IPF
Human biopsy specimens from patients with usual interstitial
pneumonia (UIP), the most common cause of IPF, compared
with age-matched controls show high galectin-3 expression in
areas of fibrotic lung (Figure 6A). Galectin-3 levels were
significantly elevated in BAL samples from patients with IPF
compared with those from age-matched control subjects (con-
trol, 18.86 3.6 ng/ml, n ¼ 16; IPF, 39.76 3.7 ng/ml, n ¼ 15; P ,
0.01) (Figure 6B, left). In addition, galectin-3 is elevated in the
serum of patients with IPF (control, 10.9 6 0.95 ng/ml, n ¼ 10;
IPF, 22.7 6 4.7 ng/ml, n ¼ 10; P , 0.05) but not in patients with
fibrotic nonspecific interstitial pneumonia (NSIP) serum con-
centration 12.57 6 0.84 ng/ml (n ¼ 10) (Figure 6B, right), which
suggests that galectin-3 may be a potential prognostic factor in
IPF.
We therefore examined serum galectin-3 in patients with rela-
tively stable IPF and those with an acute exacerbation of the dis-
ease. Serial serum galectin-3 wasmeasured at 0, 6, and 12months in
16 patients with IPF diagnosed by American Thoracic Society/
EuropeanRespiratory Society criteria. All patients were diagnosed
with IPF within the previous 6 months of study. Serum galectin-3
did not correlate with lung function or high-resolution computed
tomography score (data not shown). Three patients demonstrated
a significant decline in lung function, defined as a greater than 10%
fall in FVC and greater than 5% fall in TLCO (transfer factor of
the lung for carbon monoxide) or a greater than 20% fall in TLCO
and greater than 5% fall in FVC at 12 months. No patient had an
acute exacerbation of IPF during the 12-month period, but two
patients showed an acute rise in serum galectin-3 at 12 months
and both experienced a terminal acute exacerbation of IPF 1
month after last serum galectin measurement (Figure 6C). In
view of this observation we measured galectin-3 in serum
taken from five patients during an acute exacerbation of IPF
as previously published (26). These patients were defined as
having an acute exacerbation with increased breathlessness,
decreased lung function, and new radiographic infiltrates,
which was clinically not caused by infection. Significantly, in
these samples there was an increase in circulating fibrocytes
(26). In these patients there was a dramatic rise in serum
galectin-3 (73.8 6 12.2 ng/ml) (Figure 6D). Thus, the findings
in this small patient cohort suggest that serum galectin-3 may be
an indicator for disease activity of IPF and might be useful as
a clinical marker for disease progression. This requires further
study in a larger patient population.
Figure 5. The effect of galectin-3 on transform-
ing growth factor (TGF)-b1–induced Smad and
b-catenin signaling in primary mouse alveolar
epithelial cells (AECs). (A) Fluorescence micros-
copy of primary AECs from wild-type (WT) and
galectin-32/2 mouse stimulated with 10 ng/ml
TGF-b1 for 48 hours and stained with an anti–
b-catenin antibody (green) and DAPI (blue)
(scale bar ¼ 10 mm). (B) Primary AECs from
WT and galectin-32/2 mouse lungs were stimu-
lated with TGF-b1 for 30 minutes (Smad3) or
48 hours (b-catenin, AKT, GSK-3b) and cell
lysates were analyzed for total and phospho-
Smad3 and total and active b-catenin, pAKT,
and pSer9-GSK-3b by Western blot. (C) WT
and galectin-32/2 AECs were transfected with
1 mg TOPflash and FOPflash and treated with
5 ng/ml TGF-b1 or 10 mM LiCl for 24 hours.
Results are expressed as relative luciferase ac-
tivity and represent the mean SEM of four inde-
pendent experiments. (D) b-Catenin activation
in galectin-32/2 mouse lung in vivo. Mice were
given adenoviral TGF-b1 intratracheally and
lungs harvested after 14 days. Sections from
WT and galectin-32/2 mouse lungs mouse were
immunostained for active b-catenin (scale bar ¼ 25 mm). Nuclear staining was observed in areas of fibroproliferation in WT mice. Bar chart showing
quantification of positively stained cells in five random fields, n ¼ 6 per group. * P , 0.05 compared with WT.
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Galectin-3 Inhibition Reduces Lung Fibrosis and b-Catenin
Activation In Vivo
The bleomycinmodel of pulmonary fibrosis in the phase of estab-
lished fibrosis is a useful tool to evaluate novel antifibrotic drugs
for clinical use. After intratracheal administration of bleomycin
in WT mice there was a marked increase in galectin-3 expression
in lung and BAL fluid, which was temporally and spatially related
to fibrosis as determined by total lung collagen content and fibrosis
score (Figures 7A and 7B). At Day 15 after bleomycin-induced
lung injury, significant fibrosis is seen in WT mice. By 26 days
after bleomycin instillation, the lungs from WT mice showed
intense collagen staining in the alveolar walls and in areas of
fibroproliferation where galectin-3 staining is also seen (Figure
7A). Fibrosis was markedly attenuated in galectin-32/2 mice as
judged by immunohistochemistry (Figure 7C) and quantified by
histologic score (mean score 2.02 6 0.21 in galectin-32/2 mice
compared with 3.55 6 0.38 in WT mice; P , 0.05 at Day 26)
(Figure 7D) and total lung collagen was significantly reduced in
the lungs of galectin-32/2 mice at 15 and 26 days (365 6 44 vs.
234 6 24 mg collagen/left lobe at Day 15 for WT and galectin-
32/2 lungs, respectively, and 498 6 36 vs. 265 6 25 mg collagen/
left lobe at Day 26) (Figure 7E). We therefore used this model
to test the potential of inhibiting galectin-3 as an antifibrotic
therapy.
TD139 is a novel high-affinity inhibitor of the galectin-3 car-
bohydrate binding domain (Kd¼ 14 nM). In primary lung AECs
TD139 reduced TGF-b1–induced b-catenin translocation to the
nucleus, with most of the b-catenin remaining at the cell surface
(Figure 8B). Furthermore, TD139 blocked TGF-b1–induced
b-catenin phosphorylation as judged by Western blot analysis
(Figure 8A). We therefore went on to investigate the effect of
TD139 on the fibrotic phase of bleomycin-induced lung injury.
A total of 10 mg TD139 was instilled into the lungs of WT mice
on Days 18, 20, 22, and 24 after intratracheal bleomycin
Figure 7. Galectin-32/2 mice
show reduced fibrosis after
intratracheal bleomycin. (A)
Representative sections from
mouse lung at Days 0 and 26
days after bleomycin (33 mg
intratracheally) stained for col-
lagen (Masson trichrome) and
galectin-3. Images are repre-
sentative of n ¼ 6 mice per
group (scale bar ¼ 50 mm).
(B) Galectin-3 was measured
in bronchoalveolar lavage
(BAL) fluid by ELISA at Days
15, 21, and 26 after intratra-
cheal administration of bleo-
mycin. (C) Representative
Masson trichrome–stained sec-
tions of wild type (WT) and
galectin-32/2 mouse lung af-
ter bleomycin (scale bar ¼
100 mm). (D) Semiquantitative
fibrosis score from Masson tri-
chrome–stained sections of
WT (open bars) and galectin-
32/2 (solid bars) mouse lung.
(E) Quantification of collagen
content of lung homogenate
by sircol assay. * P , 0.05
compared with WT.
Figure 6. Galectin-3 is elevated in the lungs and serum of
patients with idiopathic pulmonary fibrosis (IPF). (A) Sec-
tions from human usual interstitial pneumonia (UIP) lung
and from age-matched control subjects were stained for
galectin-3. Galectin-3 is seen within fibroblastic foci in UIP
(scale bar ¼ 100 mm). (B) Galectin-3 was measured by
ELISA and was elevated in the bronchoalveolar lavage
(BAL) fluid (left) and serum (right) from biopsy-proved
patients with UIP and nonspecific interstitial pneumonia
(NSIP) and compared with age-matched healthy control
subjects (n ¼ 10; * P , 0.01 compared with control). (C)
Serial serum levels of galectin-3 were measured by ELISA
in 16 diagnosed patients with UIP over 12 months. Two
patients showed increased serum galectin-3 before an
acute exacerbation. (D) Age-matched control subjects
(n ¼ 10), patients with stable UIP (n ¼ 10), and patients
having an acute exacerbation of UIP (n ¼ 5). * P , 0.01.
** P , 0.001 compared with control.
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instillation and mice were culled on Day 26. In the lungs of WT
mice treated with TD139 there was marked reduction in fibrosis
and b-catenin activation accompanied by decreased galectin-3
expression as shown by immunohistochemistry (Figure 8C).
TD139 produced a significant decrease in total lung collagen
(472 6 82 vs. 304 6 22 mg collagen per lung for control and
drug-treated group, respectively; P , 0.05) (Figure 8D). This
was accompanied by a decrease in the fibrotic score from 3.8 6
0.4 to 2.6 6 0.3 (P , 0.05) (Figure 8E). TD139 had no effect on
fibrosis in the absence of bleomycin (Figure 8D; see Figure E4).
TD139 also decreased b-catenin activation in vivo as quantified
by counting positive nuclear staining using an antibody that rec-
ognizes phosphorylated b-catenin (Figure 8F). Thus, galectin-3
inhibition via TD139 can block the active fibrotic phase after
bleomycin-induced lung injury and may represent a lead thera-
peutic compound worthy of further clinical development.
DISCUSSION
This study shows that galectin-3 is an essential mediator of
TGF-b–induced lung fibrosis. This was manifest by reduced
myofibroblast activation and collagen production and reduced
TGF-b1–induced EMT of galectin-32/2 AECs. Galectin-3 de-
letion reduced phosphorylation and nuclear translocation of
b-catenin but had no effect on Smad2/3 phosphorylation. A
novel inhibitor of galectin-3, TD139, blocked TGF-b–induced
b-catenin activation in vitro and in vivo and attenuated the
late-stage progression of lung fibrosis after bleomycin. More-
over, patients with stable IPF had elevated levels of galectin-3
in the BAL fluid and serum compared with patients with NSIP
and control subjects, and this rose sharply during an acute
exacerbation suggesting that galectin-3 may be a marker of ac-
tive fibrosis in IPF.
There is increasing evidence that EMTmay be amajor source
of pathogenic myofibroblasts during pulmonary fibrogenesis and
contributes to the formation of fibroblastic foci in mice and
humans (25, 27–29). Mice expressing b-galactosidase exclusively
in lung epithelial cells express mesenchymal markers after
TGF-b1 expression in vivo (4). We show that TGF-b12induced
EMT in primary AECs is also dependent on galectin-3. It is
important to distinguish between factors that induce EMT
rather than those that stimulate the growth of contaminating
mesenchymal cells or promote the death of epithelial cells.
Our results indicate that there is no significant difference in
the proliferation of WT or galectin-32/2 fibroblasts and no ev-
idence of increased cell death between WT and galectin-32/2
AECs.
Fibrocytes express mesenchymal and hematopoietic markers
(30, 31) and are elevated in the blood of patients during an
acute fibrotic exacerbation of IPF (32) and have also been found
in IPF lung tissue (33). We found that bleomycin-induced lung
injury resulted in a marked increase in fibrocyte recruitment to
the damaged lung; however, we found no difference in fibrocyte
recruitment between WT and galectin-32/2 mice (Figure E5).
Taken together our results suggest that galectin-3 regulates
TGF-b1–mediated EMT and myofibroblast activation rather
than affecting fibroblast numbers or fibrocyte recruitment.
Our results suggest that reducing galectin-3 at the cell surface
reduces the cell surface expression of TGFbR without affecting
the total expression of TGFbR or receptor affinity for TGF-b1.
This is most likely caused by reduced cell surface receptor reten-
tion as a result of loss of galectin-3 binding to polylactosamine
residues on TGF-b receptors (34). TGF-b1 signals predominantly
by Smad-dependent pathways and Smad3-deficient mice are pro-
tected from TGF-b1–induced fibrosis (35). However, there is ev-
idence for TGF-1–induced activation of non–Smad-dependent
Figure 8. Galectin-3 inhibitor
TD139 reduces bleomycin-
induced fibrosis. Upper: pri-
mary alveolar epithelial cells
from wild-type (WT) mice
were plated and treated with
transforming growth factor
(TGF)-b1 in the presence or
absence of 10 mM TD139. (A)
Cells were lysed and analyzed
for active b-catenin, total
b-catenin, and b-actin by
Western blot. (B) Cells were
fixed and analyzed by immu-
nofluorescence staining for ac-
tive b-catenin (green) nuclei
stained with DAPI (scale bar ¼
15 mm). (C) Mice were given
0.033 mg bleomycin intratra-
cheally and then saline (bleo)
or 10 mg TD139 (TD139) was
instilled into the lungs on Days
18, 20, 22, and 24 and lungs
were harvested on Day 26 as
described in METHODS. Serial sec-
tions of mouse lung were stain-
ed with Masson’s trichrome,
galectin-3, and active b-catenin
(scale bar ¼ 20 mm) as indi-
cated. (D) Fibrosis was assessed
by lung collagen content by sircol assay (n¼ 5–6; * P, 0.01 compared with bleomycin alone) and (E) by histologic score. (F) Active b-catenin was scored
from sections of WT and TD139-treated WT mouse lungs. Nuclear staining was observed in areas of fibroproliferation in WT mice. Bar chart showing
quantification of positively stained cells in five random fields, n ¼ 6 per group. Results are representative of at least four individual experiments.
MacKinnon, Gibbons, Farnworth, et al.: Regulation of Lung Fibrosis by Galectin-3 543
signaling in EMT (36, 37), in particular, interactions between
TGF-b1 and the b-catenin pathway (38). In response to TGF-b1,
b-catenin is liberated from the E-cadherin adherens junctions and
translocates to the nucleus where it mediates activation of transcrip-
tion factors promoting collagen transcription (39, 40). However, the
predominant pathway involved in TGF-b1–mediated EMT seems
to be highly cell type and context dependent (36). Mice lacking
the a3b1 integrin show full phosphorylation of Smad2 but a re-
duced interaction of Smad2 with phosphorylated b-catenin
resulting in reduced TGF-b1–mediated EMT and fibrosis (41,
42). In MDCKII cells loss of tight junctions was Smad indepen-
dent, whereas complete loss of E-cadherin and transformation
to a mesenchymal phenotype were dependent on Smad signal-
ing (43). The role of these non-Smad pathways during EMT
in the lung is largely unknown. However, the Wnt/b-catenin
signaling pathway is aberrantly activated in IPF and nuclear
b-catenin localization is observed in cells forming fibroblast foci
(44). b-catenin and TGF-b1 can independently or cooperatively
regulate target gene transcription, which play an important role
in EMT (39, 41, 42, 45). Our results demonstrate that galectin-3
does not affect Smad3 or Smad2 activation or Smad2 associa-
tion with pTyr654–b-catenin but regulates TGF-b1–induced
EMT by cooperative regulation of the Wnt signaling pathway,
resulting in activation and nuclear translocation of b-catenin by
an inhibition of GSK-3b phosphorylation and activity. The in-
creased basal b-catenin activation in WT AECs compared with
galectin-32/2 cells is most likely a result of spontaneous EMT
observed in WT cells in culture probably caused by activation of
AECs plated on the collagen-fibronetric matrix (42). However
crucially, we saw no difference in basal b-catenin activation
in cells treated with exogenous recombinant galectin-3 and no
difference in control-treated WT and galectin-32/2 mice in vivo
suggesting that there is no real difference in basal activation
in vivo.
We suggest that although the Smad pathway is necessary it is
not sufficient to induce EMT in lung AECs. A recent study by Li
and coworkers (46) highlights the importance of lung epithelial
cell TGFR-II expression in driving EMT and fibrosis after bleo-
mycin. Interestingly, in this study deletion of TGFR-II did not
fully block TGF-b1–induced Smad signaling, which could sug-
gest additional non-Smad pathways are necessary for EMT and
fibrosis to occur. This has parallels with the present study, which
shows that reduced surface expression of TGFR-II (in the ab-
sence of galectin-3) allows Smad signaling but prevents EMT
and fibrosis. We propose that TGF-b1 increases galectin-3 ex-
pression in the fibrotic lung, which stimulates EMT and myofi-
broblast differentiation. By anchoring TGF receptors at the cell
surface, galectin-3 may provide an optimal framework that allows
the receptors to signal by the accessory pathways necessary for
full EMT to occur (Figure E6). Although the mechanisms of
this effect have yet to be defined, differential internalization of
TGF-b receptors is thought to be important for regulating the
duration and directionality of signaling (47), and that undefined
regulatory mechanisms exist that direct sequestration into differ-
ent endocytic compartments, which can either promote Smad
signaling or induce receptor degradation (48). The Snail family
of transcription factors (SNAI1 and SNAI2) is induced by TGF-b
by Smad and non-Smad pathways and function to inhibit E-cad-
herin transcription leading to the development of EMT (13, 43).
The effect of galectin-3 on the expression and function of these
transcription factors requires further study.
Galectin-3 is markedly up-regulated in fibroproliferative
areas in the lung of patients with UIP. Serum galectin-3 concen-
tration is stable over time, showing little variation during the sta-
ble phase of UIP but during an acute exacerbation, serum
galectin-3 levels rise significantly. Thus, our observations in
patients mirror those seen in mice where galectin-3 expression
correlates with the level of active fibrosis. Our results suggest
that serum galectin-3 levels may help distinguish UIP from NSIP
clinically and identify patients undergoing an acute exacerba-
tion. This requires further study in a larger patient cohort.
The bleomycin model of fibrosis is widely used as a model of hu-
man IPF (49) and as a screen to evaluate novel antifibrotic drugs for
clinical use. As with Ad–TGF-b, galectin-32/2mice were protected
from the profibrotic effects of bleomycin. In screening for antifi-
brotic drugs it is critical to distinguish between potential antiinflam-
matory and antifibrotic effects because preventing progression of
fibrosis has more clinical relevance (50–52). We administered the
galectin-3 inhibitor TD139 during the fibrotic phase of bleomycin-
induced lung injury, which fully blocked the progression of fibrosis.
TD139 is a novel synthetic inhibitor of galectin-3. TD139 has high
affinity for galectin-3 with a Kd 14 nM and galectin-1 Kd 10 nM,
but low affinity for galectins 2, 4N, 4C, 7, 8N, or 9N. In contrast
to galectin-3, which is associated with chronic inflammation, the
in vivo administration of galectin-1 prevents the development of
chronic inflammation and impairs the ongoing disease in a number
of experimental models of autoimmune diseases (53–56). Galectin-1
has been shown to suppress collagen expression and renal fibro-
sis (57). Thus, the antifibrotic effects of TD139 are most likely
caused by its blocking galectin-3 function.
Our results show that blocking galectin-3 function is both pre-
ventative and therapeutic in reducing lung fibrosis, suggesting that
galectin-3 inhibition is an exciting novel therapeutic target to treat
patients with IPF. In addition, TD139 may be a compound for fur-
ther drug development for treatment of lung fibrosis.
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